Grufity logo
Grufity logo

Latest ACUTA CAPITAL PARTNERS, LLC Stock Portfolio

$141Million– No. of Holdings #26

ACUTA CAPITAL PARTNERS, LLC Performance:
2026 Q1: 14.53%YTD: 14.53%2025: 117.97%
Performance for 2026 Q1 is 14.53%, and YTD is 14.53%, and 2025 is 117.97%.

About ACUTA CAPITAL PARTNERS, LLC and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, ACUTA CAPITAL PARTNERS, LLC reported an equity portfolio of $141.8 Millions as of 31 Mar, 2026.

The top stock holdings of ACUTA CAPITAL PARTNERS, LLC are PRAX, TERN, AADI. The fund has invested 19.3% of it's portfolio in PRAXIS PRECISION MEDICINES I and 18.4% of portfolio in TERNS PHARMACEUTICALS INC.

The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), JAZZ PHARMACEUTICALS PLC (JAZZ) and INSMED INC (INSM) stocks. They significantly reduced their stock positions in AMYLYX PHARMACEUTICALS INC (AMLX), OCULAR THERAPEUTIX INC (OCUL) and COMPASS THERAPEUTICS INC (CMPX). ACUTA CAPITAL PARTNERS, LLC opened new stock positions in ERASCA INC (ERAS), 4D MOLECULAR THERAPEUTICS INC (FDMT) and IDEAYA BIOSCIENCES INC (IDYA). The fund showed a lot of confidence in some stocks as they added substantially to SUTRO BIOPHARMA INC (STRO), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and REVOLUTION MEDICINES INC (RVMD).
ACUTA CAPITAL PARTNERS, LLC Equity Portfolio Value
Last Reported on: 15 May, 2026

ACUTA CAPITAL PARTNERS, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that ACUTA CAPITAL PARTNERS, LLC made a return of 14.53% in the last quarter. In trailing 12 months, it's portfolio return was 186.88%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
erasca inc5,737,020
4d molecular therapeutics inc2,255,390
ideaya biosciences inc1,607,160
entrada therapeutics inc1,127,700
avalo therapeutics inc907,863
New stocks bought by ACUTA CAPITAL PARTNERS, LLC

Additions

Ticker% Inc.
sutro biopharma inc299
moonlake immunotherapeutics223
revolution medicines inc209
tango therapeutics inc56.27
bright minds biosciences inc32.58
praxis precision medicines i2.25
Additions to existing portfolio by ACUTA CAPITAL PARTNERS, LLC

Reductions

Ticker% Reduced
amylyx pharmaceuticals inc-54.67
ocular therapeutix inc-43.77
compass therapeutics inc-22.34
terns pharmaceuticals inc-22.18
lb pharmaceuticals inc-3.6
taysha gene therapies inc-3.38
unicycive therapeutics inc-3.38
oculis holding ag-3.38
ACUTA CAPITAL PARTNERS, LLC reduced stake in above stock

Sold off

Ticker$ Sold
pasithea therapeutics corp-580,500
verastem inc-1,107,400
nuvation bio inc -cw27-29,975
cidara therapeutics inc-19,691,200
zymeworks inc-2,110,160
jazz pharmaceuticals plc-4,931,360
insmed inc-4,503,810
dianthus therapeutics inc-688,537
ACUTA CAPITAL PARTNERS, LLC got rid off the above stocks

Sector Distribution

ACUTA CAPITAL PARTNERS, LLC has about 89% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare89
Others11

Market Cap. Distribution

ACUTA CAPITAL PARTNERS, LLC has about 11.1% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • SMALL-CAP
  • UNALLOCATED
  • MICRO-CAP
  • MEGA-CAP
  • NANO-CAP
  • LARGE-CAP
Category%
MID-CAP43.3
SMALL-CAP22.3
UNALLOCATED11
MICRO-CAP9.3
MEGA-CAP8.4
NANO-CAP3
LARGE-CAP2.7

Stocks belong to which Index?

About 57.1% of the stocks held by ACUTA CAPITAL PARTNERS, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200057.1
Others42.9
Top 5 Winners (%)%
TNGX
tango therapeutics inc
89.6 %
STRO
sutro biopharma inc
50.3 %
NERV
minerva neurosciences
49.9 %
AADI
whitehawk therapeutics inc
42.6 %
oculis holding ag
32.6 %
Top 5 Winners ($)$
TERN
terns pharmaceuticals inc
7.0 M
TNGX
tango therapeutics inc
4.4 M
AADI
whitehawk therapeutics inc
3.5 M
PRAX
praxis precision medicines i
2.3 M
STRO
sutro biopharma inc
2.2 M
Top 5 Losers (%)%
maze therapeutics inc
-27.5 %
OCUL
ocular therapeutix inc
-23.6 %
TSHA
taysha gene therapies inc
-18.4 %
ARGX
argen se - adr
-12.9 %
DRUG
bright minds biosciences inc
-5.7 %
Top 5 Losers ($)$
OCUL
ocular therapeutix inc
-3.0 M
ARGX
argen se - adr
-0.5 M
DRUG
bright minds biosciences inc
-0.5 M
TSHA
taysha gene therapies inc
-0.5 M
maze therapeutics inc
-0.2 M

ACUTA CAPITAL PARTNERS, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ACUTA CAPITAL PARTNERS, LLC

ACUTA CAPITAL PARTNERS, LLC has 26 stocks in it's portfolio. About 77.4% of the portfolio is in top 10 stocks. OCUL proved to be the most loss making stock for the portfolio. TERN was the most profitable stock for ACUTA CAPITAL PARTNERS, LLC last quarter.

Last Reported on: 15 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions